Medasense Biometrics News
17 articles
FDA authorizes marketing of Medasense's NOL technology to measure pain in anesthetized patients | CTech
Medasense Biometrics has received marketing authorization from the FDA for its PMD-200 patient monitor with NOL technology. The technology uses a sensor platform and AI algorithms to convert data into a patients Signature of Pain and is used for monitoring nociception. It allows clinicians to personalize pain management and avoid overmedication. NOL is the first and only market-authorized technology for assessing changes in nociception in adult patients receiving opioid or opioid sparing analgesics. Medasense aims to improve pain management and pain-related outcomes for patients undergoing surgery.
Customers
Pain Monitoring Technology (NOL) is Shown to Reduce Postoperative Pain and Health Costs
A study from Leiden University in the Netherlands has found that using NOL technology from Medasense during surgery can help reduce postoperative pain, which can potentially reduce healthcare costs. The study demonstrated that patient pain scores were 33% lower when pain medication during surgery was guided with NOL monitoring. An economic analysis conducted by Coreva Scientific found that these positive outcomes could lead to a 22% reduction in healthcare costs associated with acute postoperative pain treatments. Additionally, there could be a 6% reduction in the expected number of patients receiving postoperative opioid prescriptions. Medasense offers the PMD-200 with NOL index, a non-invasive pain monitoring technology that allows clinicians to optimize and personalize pain control.
CustomersPartners
NOL Pain Response Monitoring Secures Marketing Approval in Brazil
Medasense Biometrics Ltd.s NOL pain response monitoring device has been approved for marketing in Brazil by ANVISA. The device helps surgical teams manage pain medication during surgery and applies a non-invasive sensing platform and AI algorithm to monitor and quantify the patients pain response. Studies are also being conducted to confirm the benefits of NOL monitoring in the intensive care unit for mechanically ventilated patients, including COVID-19 patients. Medasense has partnered with J.G. Moriya to establish NOL monitoring in Brazil and expects to perform the first NOL-guided surgeries in the coming weeks.
CustomersPartners
Unique pain monitor during surgery reduces post-op pain
A study in the British Journal of Anaesthesia shows that Medasenses pain response monitoring technology can help reduce postoperative pain. The device uses artificial intelligence and a noninvasive sensor platform to objectively monitor and quantify patients pain response. The study found that postoperative patient pain scores were one-third lower when pain medication during surgery was guided by the Medasense device. Additionally, stress hormone levels were up to 50 percent lower in these patients. Medasense recently raised $18 million in a series C round and is seeking FDA approval for commercialization in the United States.
CustomersInvestment
Israeli pain monitoring co Medasense raises $18m
Medasense Biometrics Ltd., an Israeli pain response monitoring company, has raised $18 million in a series C round of funding. The funding was provided by Sabadell Asabys venture capital firm, Israeli family offices, and returning investors Baxter Ventures, Olive Tree Ventures, and LGL Capital. Medasenses technology uses a multi-parametric sensor platform and advanced AI algorithms to convert complicated data into a patients Signature of Pain. The technology is currently used in operating rooms and critical care settings, enabling clinicians to personalize treatment and control pain. The company plans to expand its commercial deployment in Europe and obtain FDA approval for commercialization in the US. Medasense aims to improve pain care and reduce healthcare costs associated with postoperative pain.
InvestmentPartnersExpand
Analysis Shows Cost Benefits of Personalizing Pain Management During Surgery with NOL Technology - AI Tech
A new economic study has shown that Medasenses AI-based pain-response monitoring solution, NOL technology, is likely to help reduce the cost of care for hospitals. The study demonstrated that NOL-guided intraoperative analgesia could facilitate cost savings in under a year. NOL monitoring provides a reliable index for the surgical team to objectively detect and quantify noxious stimuli during anesthesia. The research showed that ROI could be achieved within two to five months, and depending on the country, savings of $218,000 to $417,000 in hospital expenses could be reached within one year. The study aims to increase adoption of NOL monitoring in surgical facilities.
CustomersPartners
Study Validates NOL Technology for Assessment of Pain in Mechanically Ventilated Patients
The peer-reviewed journal Pain Management Nursing has published the results of an observational study exploring the utilization of NOL® monitoring to assess pain response levels experienced by mechanically ventilated patients in the ICU. The study found that the NOL index can identify and quantify different levels of painful stimuli in these patients. Medasense, the company behind NOL technology, sees the potential value of NOL monitoring in the ICU and is conducting additional studies to confirm its benefits. The use of objective pain monitors, specifically the NOL, is recommended by recent ICU guidelines for deeply sedated and intubated COVID-19 patients.
Customers
Medasense to Provide Pain Index Solution for Treatment of Dementia Patients
Medasense Biometrics Ltd. has been awarded a development grant from the Israel Innovation Authority to extend the application of its NOL pain response monitoring index for noncommunicating dementia patients. The project will be conducted in collaboration with the Dorot Rehabilitation and Geriatric Medical Center in Netanya, Israel. The grant will enable Medasense to provide tools that can help reduce suffering for dementia patients and improve pain care and patient outcomes. Medasenses NOL technology enables clinicians to optimize and personalize pain control and avoid overmedication. The companys flagship product, the PMD-200 with its NOL index, is a unique platform that objectively monitors and quantifies the patients pain response. The companys pipeline cloud-based solutions for clinics and home address a $15B global market.
Customers
Israeli companies chosen for MedTech Innovator Showcase
Israeli biomed companies Medasense and Vectorious have been selected for MedTech Innovators 2019 Showcase program. Medasense was chosen for its AI-driven pain-management technology, while Vectorious was selected for its V-LAP product for heart failure monitoring. The companies were among 50 finalists chosen out of 800 applicants. The showcase program provides an opportunity for these companies to present their innovations on stage. Additionally, Israeli company ApiFix, which developed a minimally invasive procedure for correcting adolescent scoliosis, won a grant and access to an accelerator program.
PartnersCustomers
Israeli companies chosen for MedTech Innovator Showcase
Israeli biomed companies Medasense and Vectorious have been selected for MedTech Innovators 2019 Showcase program. Medasense was chosen for its AI-driven pain-management technology, while Vectorious was chosen for its V-LAP product for heart failure monitoring. The companies were among 50 finalists selected out of 800 applicants. The showcase program provides an opportunity for startups to present their technologies on stage. Additionally, Israeli company ApiFix, which developed a minimally invasive procedure for correcting adolescent scoliosis, won a grant and access to a Pediatric Device Innovator Accelerator Program.
PartnersCustomers
An Israeli Pain Technology Could Ebb Opioid Addiction Post-Surgery
Medasense Biometrics, an Israeli company, has developed a portable pain sensor that uses artificial intelligence algorithms to objectively assess a patients physiological response to pain. The technology aims to reduce opioid addiction post-surgery by providing doctors with real-time data on a patients pain levels and pain care needs. The companys pain sensor has already shown promising results, with a recent study reporting a 30% reduction in opioid consumption during surgery. Medasenses pain technology is commercially available in Europe, Canada, Australia, and Israel, and the company is working to enter the US market. The goal is to help curb the opioid crisis by providing personalized and optimized pain care.
Customers
Medasense Announces Compatibility with Philips IntelliVue Patient Monitors
Medasense Biometrics Ltd. now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. The partnership with Philips marks new ground in making Medasenses NOL technology the new standard of care for pain-response monitoring. The PMD-200 monitor and its NOL index help clinicians optimize patients pain management in critical care. The technology enables clinicians to have a reliable, consolidated view of changes in pain response level, integrated within their vital sign monitor and saved into their electronic medical record. Medasense aims to improve patient safety and outcomes by collaborating with industry leaders like Philips.
Partners
Medasense Announces Positive Results From Clinical Outcome Studies Using the NOL® Monitoring Technology for Optimized Pain Control
Medasense Biometrics Ltd., developer of innovative systems and applications to objectively assess the physiological response to pain, announced positive results from several studies using the NOL monitoring technology. The studies demonstrated that using the NOL technology significantly reduced opioid consumption and improved hemodynamic stability in patients undergoing major surgery. The first study showed that NOL-guided opioid administration led to 33% less intraoperative opioids and 80% less hemodynamic hypotensive events. The second study found that NOL correlated with pain at mobilization on day 1 following surgery and pain at movement 3 months following surgery. These results indicate the potential of NOL technology to improve patient care and empower clinicians in pain management.
Customers
Baxter Ventures invests in Medasense Biometrics
Israeli medical device company Medasense Biometrics has received an investment from Baxter Ventures, the investment arm of Baxter International. The investment is part of Medasenses series B financing round and will support global clinical research and market development of their flagship product PMD-200, an objective pain monitoring system. Medasense has developed technology that can assess and monitor changes in a patients pain level by processing physiological parameters affected by pain and analgesic administration. The investment from Baxter Ventures strengthens Medasenses commitment to improving patient care and optimizing pain treatment. The amount of investment has not been disclosed.
Investment
Pain monitoring co Medasense Biometrics raises $8m
Israeli pain monitoring startup Medasense Biometrics Ltd. has closed an $8 million Series B financing round. The financing was led by Benslie International Ltd. and joined by existing investors and a strategic investor - a leading global medical technology corporation. Medasense will use the new funding to accelerate commercialization of its flagship product PMD-200: An objective pain monitoring system for operating rooms and critical care. The system consists of a non-invasive finger probe that records multiple pain-related physiological signals, and the PMD-200 monitor, which uses a composite algorithm to determine an individuals real-time pain level index NoL. The technology has been validated in clinical studies and outperforms currently used parameters and methods.
InvestmentExpand
Medasense's Pain Assessment Monitor Among Winners Of Prestigious Startup Competition
Israeli biomed startup Medasense has developed a technology that mathematically measures pain to help doctors assess patients. The companys flagship product is a non-invasive pain monitoring device that uses statistical tools to give an objective pain reading. The device is expected to receive approval from the EU in the coming months. Medasense has raised $5 million in private rounds. The company was announced as one of the winners of the startup competition at the Israel Advanced Technology Industries (IATI) Biomed Conference.
CustomersInvestment
